Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions
Authors
Keywords
-
Journal
Cancer Management and Research
Volume Volume 12, Issue -, Pages 10411-10421
Publisher
Informa UK Limited
Online
2020-10-21
DOI
10.2147/cmar.s265828
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
- (2020) Kazushige Yoshida et al. BMC CANCER
- α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas
- (2019) E. Dodagatta-Marri et al. Journal for ImmunoTherapy of Cancer
- Transforming Growth Factor-β Signaling in Immunity and Cancer
- (2019) Eduard Batlle et al. IMMUNITY
- PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
- (2019) Takahiro Kamada et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody
- (2019) Tao Dao et al. OncoImmunology
- Application of PD-1 Blockade in Cancer Immunotherapy
- (2019) Xiaomo Wu et al. Computational and Structural Biotechnology Journal
- Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma
- (2019) Jian Chen et al. TRENDS IN MOLECULAR MEDICINE
- Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
- (2019) Spencer C. Wei et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- T Regulatory Cells and Priming the Suppressive Tumor Microenvironment
- (2019) Christina M. Paluskievicz et al. Frontiers in Immunology
- A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
- (2018) Xuexiang Du et al. CELL RESEARCH
- Long non-coding RNA NEAT1 plays an important role in sepsis-induced acute kidney injury by targeting miR-204 and modulating the NF-κB pathway
- (2018) Yi Chen et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
- (2018) Young Kwang Chae et al. Journal for ImmunoTherapy of Cancer
- Roles of the immune system in cancer: from tumor initiation to metastatic progression
- (2018) Hugo Gonzalez et al. GENES & DEVELOPMENT
- Identification and validation of a tumor-infiltrating Treg transcriptional signature conserved across species and tumor types
- (2018) Angela M. Magnuson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Transforming of the Tumor Microenvironment: Implications for TGF-β Inhibition in the Context of Immune-Checkpoint Therapy
- (2018) Stefanie Löffek Journal of Oncology
- Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
- (2017) Frederick Arce Vargas et al. IMMUNITY
- Treg therapy in transplantation: a general overview
- (2017) Marco Romano et al. TRANSPLANT INTERNATIONAL
- Regulation of the Immune Response by TGF-β: From Conception to Autoimmunity and Infection
- (2017) Shomyseh Sanjabi et al. Cold Spring Harbor Perspectives in Biology
- Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy
- (2016) Kazuhide Sato et al. Science Translational Medicine
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- PD-1 Blockade Expands Intratumoral Memory T Cells
- (2016) A. Ribas et al. Cancer Immunology Research
- Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial
- (2016) Jason J. Luke et al. Journal for ImmunoTherapy of Cancer
- FOXP3+ regulatory T cells and their functional regulation
- (2015) Zhiyuan Li et al. Cellular & Molecular Immunology
- Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients
- (2015) K. Kurose et al. CLINICAL CANCER RESEARCH
- Immunotherapy Approaches in Cancer Treatment
- (2015) Pavel Klener et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Cancer immunotherapy: harnessing the immune system to battle cancer
- (2015) Yiping Yang JOURNAL OF CLINICAL INVESTIGATION
- Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
- (2015) Emanuela Romano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis
- (2015) Bin Shang et al. Scientific Reports
- Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study
- (2015) Luana Calabrò et al. Lancet Respiratory Medicine
- Transient Ablation of Regulatory T cells Improves Antitumor Immunity in Colitis-Associated Colon Cancer
- (2014) E. Pastille et al. CANCER RESEARCH
- Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
- (2014) Michinori Ogura et al. JOURNAL OF CLINICAL ONCOLOGY
- Current status of interleukin-10 and regulatory T-cells in cancer
- (2013) Kristen L. Dennis et al. CURRENT OPINION IN ONCOLOGY
- Treg and CTLA-4: Two intertwining pathways to immune tolerance
- (2013) Lucy S.K. Walker JOURNAL OF AUTOIMMUNITY
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
- (2013) Luana Calabrò et al. LANCET ONCOLOGY
- Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans
- (2013) D. Sugiyama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer Immunotherapy
- (2013) J. Couzin-Frankel SCIENCE
- T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
- (2012) A. Facciabene et al. CANCER RESEARCH
- The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature
- (2012) R. J. deLeeuw et al. CLINICAL CANCER RESEARCH
- CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients
- (2012) A. J. Rech et al. Science Translational Medicine
- T Cell Surveillance of Oncogene-Induced Prostate Cancer Is Impeded by T Cell-Derived TGF-β1 Cytokine
- (2011) Moses K. Donkor et al. IMMUNITY
- Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
- (2011) Andrea Facciabene et al. NATURE
- Multiple Antitumor Mechanisms Downstream of Prophylactic Regulatory T-Cell Depletion
- (2010) Michele W.L. Teng et al. CANCER RESEARCH
- Granzymes in cancer and immunity
- (2010) S P Cullen et al. CELL DEATH AND DIFFERENTIATION
- Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients
- (2010) J. F. M. Jacobs et al. CLINICAL CANCER RESEARCH
- Methylation matters: binding of Ets-1 to the demethylated Foxp3 gene contributes to the stabilization of Foxp3 expression in regulatory T cells
- (2010) Julia K. Polansky et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Epigenetic mechanisms of regulation of Foxp3 expression
- (2009) G. Lal et al. BLOOD
- Regulatory T cells exert checks and balances on self tolerance and autoimmunity
- (2009) Kajsa Wing et al. NATURE IMMUNOLOGY
- CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
- (2008) B. Kavanagh et al. BLOOD
- Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines
- (2008) M. A. Morse et al. BLOOD
- Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade
- (2008) A. Ribas et al. CLINICAL CANCER RESEARCH
- Regulatory T cells in health and disease
- (2008) Ciriaco A. Piccirillo CYTOKINE
- DNA methylation controls Foxp3 gene expression
- (2008) Julia K. Polansky et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
- (2008) C. I. Liakou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search